Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Guérin, Annie; Hao, Yanbin; Tang, Derek; Peeples, Miranda; Fang, Anna; Kageleiry, Andrew; Koo, Valerie; Li, Nanxin; Wu, Eric Q.

doi:10.1080/14656566.2016.1176148

Cited by 4 publications

(3 citation statements)

References 18 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…In another study, 11% of MBC patients reported clinically elevated levels of depressive symptoms and anxiety 5 years after diagnosis [18]. Additionally, some MBC patients experience barriers to oncologic treatment adherence [19] and persistence [20], whereas others demonstrate high rates of adherence and persistence [21, 22]. Finally, with regard to health behaviors, the majority of MBC patients report marked sleep disturbances [23, 24] and less daily physical activity [25] than women without cancer, which is important given that sleep quality and physical activity predict mortality [26, 27].…”

Section: Introductionmentioning

confidence: 99%

Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)

Williamson

Love

DeHart

et al. 2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 99%

Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)

Williamson

Love

DeHart

et al. 2018

Breast Cancer Res Treat

View full text Add to dashboard Cite

show abstract

“…Guérin et al [14] reported the treatment patterns and factors associated with everolimus treatment among 902 postmenopausal women with HR+/HER2− mBC using the Truven MarketScan and IMS Health PharMetrics databases. Similar to our results, they observed that approximately 80% of patients initiated everolimus at a dose of 10 mg daily and noted that less than 5% of patients experienced a dose increase relative to the index dose, whereas approximately 20% of patients experienced a dose reduction.…”

Section: Discussionmentioning

confidence: 99%

Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer

et al. 2020

View full text Add to dashboard Cite

Background There is limited literature on patterns of everolimus use and subsequent hospitalizations and emergency room (ER) visits in real‐world clinical practice. In this study, we describe patterns of everolimus use and hospitalizations and ER visits in a large cohort of patients with breast cancer (BC). Materials and Methods Patients with BC treated with everolimus were identified in the MarketScan database from 2009 to 2016. The pattern of everolimus use and frequency of associated ER visits and hospitalizations during treatment (between the first claim and 30 days after the last claim for everolimus) were identified. Descriptive statistics and regression models were used. Results A total of 3,556 everolimus users were identified (median age of 60 years; median days of use, 112). The initial prescribed dose was 10 mg in 74.8% of the patients. Compared with the initial dose, 23.5% of patients had a dose change. Forty‐six percent of patients were hospitalized or had an ER visit during the treatment with everolimus. Age greater than 71, higher comorbidity score, treatment year prior to 2012, and lower initial dose were found to be significantly associated with ER visit/hospitalization in the regression models. Conclusions A significant proportion of patients receiving everolimus had an ER visit or hospitalization during the use of everolimus. These results provide data regarding risks and benefits of treatment with everolimus. These results will be helpful in identifying patients at higher risk of hospitalizations or ER visits and facilitate evidence‐based decision making to avoid serious complications. Implications for Practice Everolimus, a mammalian target of rapamycin inhibitor, is approved in combination with exemestane in patients with hormone receptor–positive tumors previously treated with anastrozole or letrozole. As new drugs become available, it is crucial to understand the adverse events and potential complications associated with the use of such drugs in the general population, outside of the controlled clinical trial setting. This study describes the patterns of everolimus use and adverse events, including hospitalization and emergency room visits, in a large cohort of patients with metastatic breast cancer in routine practice.

show abstract

“…A retrospective study showed that everolimus is more effective in ER (+), PR (+), and HER2 (-) patients with bone and visceral metastases than endocrine monotherapy. The remission rate of the patients treated with everolimus was >80%, whereas that of the patients that received endocrine monotherapy was 60%–70% 16 . However, the use of everolimus should be limited owing to its severe adverse effects, such as stomatitis, rash, non-infectious pneumonitis, diarrhea, and hot flushes 17 .…”

Section: Introductionmentioning

confidence: 89%

Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway

Shi

Zhang

et al. 2018

Cancer Biology & Medicine

View full text Add to dashboard Cite

A postmenopausal patient with a diagnosis of estrogen receptor (ER) (+), progesterone receptor (PR) (+), and human epidermal growth factor receptor-2 (HER2) (-) breast cancer was reported. The patient refused surgery and was resistant to conventional chemotherapy regimens. Computed tomography and the circulating tumor cell test indicated that the patient’s tumor burden increased rapidly even after several chemotherapy sessions. Multiple genetic aberrances in the phosphatidylinositol3-kinases (PI3K) signaling pathway were detected via next-generation sequencing (NGS)-based liquid biopsy, including a p. G1007R missense mutation in exon 21 of PIK3CA (33.61%), a p.L70fs frameshift mutation in exon 3 of phosphatase and tension homolog deleted on chromosome ten (PTEN) (49.14%), and a p. D1542Y missense mutation in exon 32 of mammalian target of rapamycin (mTOR) (1.66%). Therefore, only the mTOR inhibitor everolimus was administered to the patient. Partial remission (PR) was observed after 2 months, and sustained stable disease (SD) was observed after a year and a half. Subsequent sequencing showed that the mutation ratio of PIK3CA decreased to 4.17%, and that the PTEN and mTOR mutations disappeared, which revealed the significant curative effect of everolimus. We report the first case of successful monotherapy treatment using everolimus in a patient with advanced breast cancer bearing mutations in genes involved in the PI3K/ARK/mTOR signaling pathway. The success of this case highlights the invaluable clinical contribution of NGS-based liquid biopsy, as it successfully provided an optimal therapeutic target for the patient with advanced breast cancer.

show abstract

Treatment patterns and factors associated with the use of everolimus among post-menopausal women with HR+/HER2- metastatic breast cancer: a retrospective US claims study

Cited by 4 publications

References 18 publications

Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)

Metastatic Breast Cancer Collateral Damage Project (MBCCD): Scale development and preliminary results of the Survey of Health, Impact, Needs, and Experiences (SHINE)

Real-World Patterns of Everolimus Use in Patients with Metastatic Breast Cancer

Benefit of everolimus as a monotherapy for a refractory breast cancer patient bearing multiple genetic mutations in the PI3K/AKT/mTOR signaling pathway

Contact Info

Product

Resources

About